1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2029

Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2029

  • March 2021
  • 133 pages
  • ID: 6058302
  • Format: PDF
  • GlobalData

Summary

Table of Contents

Search Inside

Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2029

Summary
Type 1 Diabetes (T1D), is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin.Insulin is the hormone that is needed for the transport of glucose from blood into cells, and without it the body is driven into a hyperglycemic state.

Left untreated, this leads to death.There is no cure for T1D, and it is managed as a chronic condition through injections of exogenous insulin.

There are other types of diabetes such as Type 2 Diabetes (developed resistance to insulin), gestational diabetes, latent autoimmune diabetes in adults, and diabetes that occurs as a symptom of other diseases. This report focuses on T1D.

The launch of the first disease-modifying therapeutics will be the main drivers of growth over the forecast period, with the first preventative therapeutic for T1D, Teplizumab, expected to launch in the US during the forecast period.Other major drivers for the T1D market include the increased T1D diagnosed prevalence, and the uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs.

Based on the epidemiological analysis , the diagnosed prevalent cases of T1D in the 8MM will grow by 17.79% over the next decade, from 3,329,294 prevalent cases in 2019 to 3,921,695 prevalent cases in 2029, at an Annual Growth Rate (AGR) of 1.78% per year in the eight major pharmaceutical markets (8MM) covered in this report, the US, 5EU (France, Germany, Italy, Spain, and UK), Japan and Canada.

The analyst projects the therapeutic market for T1D within the 8MM will grow from $4.9B in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $24B by 2029. In particular, The analyst expects the US market will contribute the most to the T1D market’s growth, contributing $4.3B sales in 2019 (87.7% of the T1D market) and $20.3B in 2029 (84.7% of the T1D market).

The consensus among interviewed physicians regarding the current treatment landscape was that while there are a number of insulin treatment options, there are a significant number of patients that are ineffectively managed, and therefore are considerably high unmet needs within the indication.Key Opinion Leaders (KOLs) interviewed highlighted the lack of a no disease-modifying therapeutic that combats the autoimmune-mediated attack of beta cells in T1D patients.

Other major issues include glycemic control, addressing obesity, and overall disease management. Despite a number of drugs currently in development, research suggests that the future level of attainment of these unmet needs will be modest, and a relatively high level of opportunity exists for drug developers to enter the T1D market.

Key Highlights
- The diagnosed prevalence of T1D is expected to increase over the 10-year forecast period due changing population demographics, and an increased understanding of risk factors and environmental factors that may trigger the onset of T1D.
- The potential launch of 5 disease-modifying therapeutics will increase the number of patients who, at diagnosis, can prolong their endogenous insulin secretion to improve disease management. These drugs are expected to have a high annual cost of therapy (ACOT), a factor that will contribute to notable profitability.
- The increasing trend of device integration into the treatment and management of T1D will impact the therapeutics that find success in the market. The drive toward closed-loops systems, like an artificial pancreas, places a great need for ultra-fast insulins to launch in the market, and prompts more collaboration between across the industry.
- Despite the variety of insulins currently available to T1D patients, there is still room for improvement within the treatment space. The most recognizable is the need for novel treatment options for refractory patients.

KEY QUESTIONS ANSWERED

Despite the existence of numerous well-established treatment options in the T1D space, a few-yet significant-unmet needs remain.
- Which unmet needs are the most pressing in the 8MM?
- Where should pharmaceutical companies focus drug development efforts in order to become a significant player in the space?

Novel insulins continue to be developed, and the first disease-modifying therapeutics may emerge over the forecast period.
- What are the most promising late-stage candidates and how much they expected to generate over the forecast period?
- What do KOLs say about their clinical and commercial positioning?

The T1D market has been dominated by three main companies since the discovery of insulin 100 years ago, though more recently new players have started to emerge.
- Which have been historically the companies leading the way?
- What new companies are emerging in the space?

Scope
- Overview of T1D including epidemiology, disease etiology and management.
- Topline T1D drugs market revenue (including off-label adjunct therapeutics used for metabolic benefits), annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of current and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU, Japan and Canada over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global angina pectoris therapeutics market. Insightful review of the key industry drivers, restraints and challenges.

Reasons to Buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global T1D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T1D market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T1D therapeutics market from 2019-2029.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Type 1 Diabetes - Epidemiology Forecast to 2029

  • $ 3995
  • March 2021
  • 43 pages

Type 1 Diabetes - Epidemiology Forecast to 2029 Summary Type 1 Diabetes (T1D), formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young ...

  • World
  • Type 1 Diabetes
  • Industry analysis
  • Diabetes Prevalence
  • Prescription Drug Sales

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on